Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced Cutaneous T-Cell Lymphoma
6 vistas
• 08/09/23
0
0
Empotrar
administrator
Suscriptores
Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the scenarios in which she has seen the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma (CTCL).
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios